vTv Therapeutics Inc (VTVT NASDAQ) stock market data APIs
$29.9958
0.25(0.8%)
as of November 17, 2025
Try our APIs with
free plan!
vTv Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina.
Prev. Close
29.9958
Open
30.2502
High
30.6164
Low
29.6555
52 wk Range
13.15-33.062
Market Cap
123 M
Shares Outstanding
3 938 K
Revenue
17 000
EPS
-1.08
Beta
0.525
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with vTv Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get vTv Therapeutics Inc data using free add-ons & libraries
Get vTv Therapeutics Inc Fundamental Data
vTv Therapeutics Inc Fundamental data includes:
- Net Revenue: 17 000
- EBITDA: -29 779 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-30
- EPS/Forecast: -0.98
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
vTv Therapeutics Inc News
New
vTv Therapeutics GAAP EPS of -$1.08 misses by $0.11
* vTv Therapeutics press release [https://seekingalpha.com/pr/20298026-vtv-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (VTVT [https://seekingalpha.com/sy...
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issu...
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appo...
vTv Therapeutics registers 15.9M Class A shares for potential resale
* vTv Therapeutics (VTV [https://seekingalpha.com/symbol/VTV]) registered 15.88M Class A common shares for resale by selling stockholders. * Includes 2.13M outstanding shares, plus shares issuable...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
